Low bone mineral density (BMD) is common in childhood leukemia and lymphoma survivors.
Medicare could save billions of dollars if secondary fractures could be prevented with improved osteoporosis screening.
A meta-analysis found that teriparatide and denosumab may be the most efficacious therapy for prevention of glucocorticoid-induced vertebral fractures.
Researchers conducted this study to determine whether bone bridge formation was correlated with low bone mineral density in patients with ankylosing spondylitis.
Patients with greater BMD improvement after 1 year of denosumab are more likely to lose BMD after the transition to alendronate therapy in the second year.
The study, presented at the American Society for Bone and Mineral Research 2019 Annual Meeting, described the experience of patients who initiated treatment with abaloparatide.
Researchers investigated the safety and efficacy of twice-weekly 28.2 μg teriparatide compared with once-weekly 56.5 μg teriparatide in Japanese patients with osteoporosis.
For postmenopausal women with osteoporosis, combined treatment with teriparatide 40 μg and denosumab can increase spine and hip bone mineral density more significantly than standard combination therapy.
Researchers assessed the effect of genetically predicted higher serum calcium levels on bone mineral density and the risk for fracture, using Mendelian randomization.
Premenopausal women who undergo prophylactic bilateral salpingo-oophorectomy are especially prone to postoperative bone loss, which may be mitigated by hormone replacement therapy.